SmithOnStocks Opines on Stocks May 19, EditionOne Approach for Investing in Emerging Biotechnology Stocks Transcept: Throwing in the Towel on Intermezzo (TSPT, $3.56)Intermezzo was launched by Transcept’s marketing partner Purdue in April 2012. I believed then and now that it is a… Transcept: Throwing in the Towel on Intermezzo (TSPT, $3.59)Intermezzo was launched by Transcept’s marketing partner Purdue in April 2012. I believed then and now that it is a… Transcept: The Prescription Trend Watch for Intermezzo is On (TSPT, $6.63)Introduction Transcept: Purdue Fires Big Marketing Guns and FDA Issues Insomnia Drug Guidelines That Help Intermezzo (TSPT, $5.72)Investment Opinion Transcept: Direct to Consumer Advertising Campaign Could be the Tipping Point for IntermezzoInvestment Overview The launch of Intermezzo began on April 4, 2012 and so far, it has been disappointing for investors. Purdue… The Launch of Transcept's Intermezzo by Purdue Has Begun (TSPT, $10.92)Investment Opinion and Overview Investors' Concerns About the Intermezzo Launch Weighs on the Stock and Creates a Buying OpportunityInvestment View I believe that Transcept’s (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success.… Investors' Concern About Launch of Intermezzo Weighs on the Stock and Creates a Buying Opportunity (TSPT, $8.21)Investment View Transcept to Resubmit Intermezzo NDA; Hopes for a Class I ReviewResubmission of Intermezzo NDA Transcept Pharmaceuticals in a press release today (September 15) said that it plans to resubmit its NDA… Transcept to Resubmit Intermezzo NDA; Hopes for a Class I Review (TSPT, $6.63)Resubmission of Intermezzo NDA Transcept Investment ThesisTranscept just released a press release on July 12, 2011 with disappointing news on Intermezzo. The release reads as follows: “Transcept… Intermezzo is Likely to be Approved on its July 14, 2011 PDUFA Date; Then What (TSPT, $7.98)Investment Thesis Transcept Releases Results of Highway Driving Study for Intermezzo and Plans to Re-Submit NDA in the First Quarter of 2011 (TSPT, $6.61)Transcept believes that the results of the highway driving study of Intermezzo reasonably answer the concerns of the FDA that… |